Long-Term Ixekizumab Treatment Acceptably Safe in Plaque Psoriasis

Cancer breath test begins trial
January 10, 2019
Methotrexate Reduces Cardiovascular Risk in Elderly-Onset Rheumatoid Arthritis
January 10, 2019
Show all

Long-Term Ixekizumab Treatment Acceptably Safe in Plaque Psoriasis

Patients with moderate to severe plaque psoriasis typically require long-term treatment to achieve disease control.

According to study results published in the Journal of the European Academy of Dermatology and Venereology, long-term treatment with ixekizumab is not associated with any new safety signals and should be considered acceptably safe and tolerable for the treatment of moderate to severe plaque psoriasis.

Previous studies have shown ixekizumab to be effective with no unexpected safety signals to treat chronic psoriasis in a short-term treatment period up to 24 weeks. The investigators of this study sought to evaluate the long-term safety and tolerability of ixekizumab for treating patients with moderate to severe plaque psoriasis for up to 3 years.

The present analysis reported the cumulative safety data on up to 319 weeks of ixekizumab exposure in a cohort of 5689 adults with moderate to severe psoriasis recruited from 11 clinical studies. The primary outcomes were treatment-emergent adverse events, including serious infections, oral candidiasis, major adverse cerebrocardiovascular events, non-melanoma skin cancer, malignancies, and inflammatory bowel disease. Adjusting for exposure period, the investigators reported the incidence rates (IR) per 100 patient-years; frequencies and exposure-adjusted incidence rates were summarized by 12-week intervals through 156 weeks (3 years).

Read on: Long-Term Ixekizumab Treatment Acceptably Safe in Plaque Psoriasis

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.